Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 3/20 | 0.53 |
| ▸ | MAOA | P21397 | 3/20 | 0.48 |
| ▸ | MAOB | P27338 | 3/20 | 0.48 |
| ▸ | MTTP | P55157 | 2/20 | 0.46 |
| ▸ | APOB | P04114 | 1/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.43 |
| ▸ | FYN | P06241 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | VCP | P55072 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7909108 | 1.00 | SMO (0.53) | SMOMAOAMAOBMTTPAPOB | |
| Hydrochloric Acid SCHEMBL7906095 | 0.99 | SMO (0.53) | SMOMAOAMAOBMTTPAPOB | |
| SCHEMBL7907542 | 0.84 | GRIN2B (0.66) | SMOMAOAMAOBGRIN2BKDM1A | |
| Hydrochloric Acid SCHEMBL10447026 | 0.84 | SMO (0.52) | SMOMAOAMAOBMTTPAPOB | |
| SCHEMBL6488557 | 0.80 | SIGMAR1 (0.52) | SMO | |
| SCHEMBL7972733 | 0.76 | HDAC8 (0.51) | GRIN2BSMN1; SMN2 | |
| SCHEMBL5539196 | 0.74 | MAOA (0.61) | MAOAMAOBKDM1AL3MBTL1SMN1; SMN2 | |
| SCHEMBL29785655 | 0.74 | MAOA (0.61) | MAOAMAOBKDM1AL3MBTL1SMN1; SMN2 | |
| SCHEMBL662711 | 0.74 | MAOA (0.57) | MAOAMAOBKDM1AL3MBTL1VCP | |
| SCHEMBL1732541 | 0.74 | MAOA (0.61) | MAOAMAOBKDM1AL3MBTL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306149-A1 | USE OF BIARYLCARBOXAMIES IN THE TREATMENT OF HEDGEHOG PATHWAY-RELATED DISORDERS | NOVARTIS AG (CH) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306149-A1 | USE OF BIARYLCARBOXAMIES IN THE TREATMENT OF HEDGEHOG PATHWAY-RELATED DISORDERS | GLI1, SHH, GLI2 | SMO 4/4885MAOA 4752/4885MAOB 4619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.